The Latest Breaking News from biotech

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

The biotech industry is well-positioned for solid growth thanks to the increasing demand for effective treatments for chronic diseases, a rapidly aging population, the adoption of technologies like AI, and government initiatives. To capitalize on the biotech industry’s growth prospects, should one consider investing in biotech stocks Puma Biotechnology (PBYI),…

The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech stocks ProQR Therapeutics (PRQR), Foghorn Therapeutics (FHTX), Harmony Biosciences (HRMY), and Organogenesis Holdings (ORGO) with massive buy potential. Keep reading.

The biotech industry is well poised to flourish, buoyed by its commitment to innovation and potential for groundbreaking discoveries. Thus, investing in the shares of three fundamentally solid biotech companies, Foghorn Therapeutics (FHTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD), might be prudent. Continue reading….

Amid the use of advanced technologies, personalized medicines, demand for quality treatments and therapies, and an aging population, the biotech industry appears to be on a steady path for expansion. Given this backdrop, let’s analyze the fundamentals of Biogen (BIIB), BioNTech (BNTX), and Kura (KURA) to determine which of these…

The biotech industry is expanding as a result of consistent technological advancements and rising investments. So, it could be wise to buy quality biotech stocks Equillium (EQ), Shionogi (SGIOY), and Theratechnologies (THTX) in 2024. Read on.

The biotech industry’s expansion stems from advancements in cutting-edge medical technologies and the growing demand for food biotechnology. Against this backdrop, should you buy Harmony Biosciences Holdings (HRMY), Exelixis (EXEL), and Surrozen (SRZN)? Let’s find out.

The biotech industry is poised for long-term growth, supported by the advancements in personalized medicine and integration with information technology. While leading biotech stocks Moderna (MRNA) and Exelixis (EXEL) should benefit from the industry tailwinds, let us predict which stock is worth buying.

The biotech industry is thriving amid innovation, demand, adaptability, and technological advancements, demonstrating resilience and adaptability. So, it could be wise to invest in quality biotech stocks Protalix BioTherapeutics (PLX), Alnylam Pharmaceuticals (ALNY), and Jazz Pharmaceuticals (JAZZ). Read on.